arwr-ex991

PASADENA, Calif., August 3, 2017 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 59285619.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and enter Conference ID 59285619.

ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)

	Three Months Ended June 30,						Nine Months Ended June 30,
OPERATING SUMMARY	2017			2016			2017			2016

REVENUE	$	9,342,498		$	39,583		$	22,693,923		$	127,083
OPERATING EXPENSES
Research and development		6,906,016			9,423,195			23,409,892			29,782,854
Salaries and payroll-related costs		3,421,089			4,113,262			11,281,194			12,281,841
General and administrative expenses		1,853,669			2,275,628			5,330,717			8,045,571
Stock-based compensation		1,713,228			2,750,785			5,881,901			7,547,967
Depreciation and amortization		1,162,660			818,200			3,535,915			2,416,461
TOTAL OPERATING EXPENSES		15,056,662			19,381,070			49,439,619			60,074,694
OPERATING LOSS		(5,714,164	)		(19,341,487	)		(26,745,696	)		(59,947,611	)
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES		194,423			(79,256	)		3,097,287			446,595
NET LOSS	$	(5,519,741	)	$	(19,420,743	)	$	(23,648,409	)	$	(59,501,016	)

NET LOSS PER SHARE (BASIC AND DILUTED):	$	(0.07	)	$	(0.32	)	$	(0.32	)	$	(1.00	)
WEIGHTED AVERAGE SHARES OUTSTANDING		74,772,103			59,966,955			73,603,852			59,764,129

FINANCIAL POSITION SUMMARY	June 30,			September 30,
	2017			2016
CASH AND CASH EQUIVALENTS	$	38,383,135		$	85,366,448
SHORT-TERM INVESTMENTS		36,754,754			-
TOTAL CASH RESOURCES (CASH AND INVESTMENTS)		75,137,889			85,366,448
OTHER ASSETS		39,943,660			42,810,057
TOTAL ASSETS		115,081,549			128,176,505
TOTAL LIABILITIES		25,539,265			33,152,246
TOTAL STOCKHOLDERS' EQUITY		89,542,284			95,024,259
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	115,081,549		$	128,176,505

SHARES OUTSTANDING		74,772,103			69,746,685

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.